Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 1.00 |
| ▸ | MMP14 | P50281 | 3/20 | 1.00 |
| ▸ | MMP2 | P08253 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | MMP10 | P09238 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921057 | 0.93 | MMP13 (0.88) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL7918685 | 0.92 | MMP13 (0.86) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL1313126 | 0.92 | MMP13 (1.00) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL1313634 | 0.90 | MMP13 (1.00) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL1313866 | 0.90 | MMP13 (1.00) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL1313430 | 0.89 | MMP13 (0.86) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL1314185 | 0.87 | MMP13 (1.00) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL1314304 | 0.86 | MMP13 (1.00) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL1316395 | 0.84 | MMP13 (0.73) | MMP13MMP14MMP2DRD5AURKA | |
| SCHEMBL12122314 | 0.84 | MMP13 (0.81) | MMP13MMP14MMP2DRD5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269138-A1 | MMP13 AS A THERAPEUTIC TARGET FOR ALLERGIC INFLAMMATORY DISEASES | MASSACHUSETTS GEN HOSPITAL (US) | 2024-08-15 | — | — | US | claimed |
| WO-2022251824-A1 | MMP13 AS A THERAPEUTIC TARGET FOR ALLERGIC INFLAMMATORY DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2022-12-01 | — | — | WO | claimed |
| US-20250228875-A1 | METHODS OF TREATING, AMELIORATING AND/OR PREVENTING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA AND HETEROTOPIC OSSIFICATION, AND KITS FOR THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-07-17 | — | — | US | disclosed |
| EP-4499131-A2 | METHODS OF TREATING, AMELIORATING AND/OR PREVENTING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA AND HETEROTOPIC OSSIFICATION, AND KITS FOR THE SAME | The Trustees of The University of Pennsylvania (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119365210-A | Methods and kits for treating, ameliorating and/or preventing progressive ossified fibrous tissue dysplasia and ectopic ossification | 宾夕法尼亚大学董事会 | 2025-01-24 | — | — | CN | disclosed |
| US-20240269138-A1 | MMP13 AS A THERAPEUTIC TARGET FOR ALLERGIC INFLAMMATORY DISEASES | MASSACHUSETTS GEN HOSPITAL (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2023192880-A2 | METHODS OF TREATING, AMELIORATING AND/OR PREVENTING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA AND HETEROTOPIC OSSIFICATION, AND KITS FOR THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2022251824-A1 | MMP13 AS A THERAPEUTIC TARGET FOR ALLERGIC INFLAMMATORY DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-2340243-B1 | HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-08 | — | — | EP | disclosed |
| EP-2340243-B1 | HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-8785489-B2 | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8785489-B2 | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20110275631-A1 | Heteroaryl Substituted Indole Compounds Useful as MMP-13 Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275631-A1 | Heteroaryl Substituted Indole Compounds Useful as MMP-13 Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2340243-A1 | HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010045188-A1 | HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045188-A1 | HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275631-A1 | Heteroaryl Substituted Indole Compounds Useful as MMP-13 Inhibitors | MMP13, MMP3, MMP11 | MMP13 1/4885MMP14 9/4885MMP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.